Skip to main content

Table 1 Demographics, clinical features, PEG-J procedures and related complications

From: PEG-J replacement for duodenal levodopa infusion in Parkinson’s disease patients: a retrospective study

n=30
 Male 60%       
 Age at disease onset (y) 53.9 (35-62) ± 6.8     
 Age at PEG-J placement 69.4 (51-80) ± 6.4     
 Age at LFV (y) 724 (61-82) ± 5.6     
 Disease duration (y) 17.2 (10-33) ± 5.7     
 Disease duration at PEG-J placement (y) 14.9 (6-28) ± 6.3     
 Follow-up duration (mo) 61.3 (3-119) ± 32.6     
 Active follow-up 23       
 Patients acquired from other sites 3       
 Deceased 6       
 Discontinued 1       
Patients with 23 (11-38) ± 8.2 months of follow-up (n=20)
  baseline   LFV
 MDS-UPDRS pt. III score 31.6 (4-50) ± 14   33.5 (8-66) ± 15.2
 mH&Y stage 3 (2.5-4) ± 0.5   3 (2.5-4) ± 0.6
 Weight (kg) 57.5 (38-76) ± 10.8   57 (36-75) ± 11.3
 Morning dose (ml) 7.8 (3.6-12.5) ± 2.7   8.1 (3.6-12.6) ± 1.8
 Continuous infusion (ml/h) 3.1 (2-4.3) ± 0.7   3.3 (2-4.6) ± 0.8
 Extra dose (ml) 2.2 (1.3-3.5) ± 0.6   2.2 (0.5-3.5) ± 0.8
 Average extra doses per day 1.2 (0-3) ± 1.0   1.2 (0-5) ± 1.1
 Daily DLI dose (mg) 1072 (710-1486) ± 236.4   1152 (708-1698) ± 262
PEG-J procedures (n=156)
 First implants 30       
 Scheduled replacements 53       
 Not scheduled (unexpected) replacements 73       
Complications related PEG-J replacements Events Patients      
Device-related
 Accidental removal 1 1      
 Device coloring 8 4      
 Tube breaking/puncture 16 6      
 Ext./int. bumper dislocation 21 9      
 Candida colonization 1 1      
 Tube dislocation 35 12      
Patient-related        
 Abdominal discomfort 9 5      
 Granulation tissue 4 4      
 Buried bumper syndrome 1 1      
 Peristomal inflammation 4 4      
Total 100       
Stoma complicationsa
 Candida infection 1 1      
 Granuloma 9 3      
 Erythema 44 13      
 Serous secretions 20 3      
 Sero-ematic secretions 2 1      
 Purulent secretions 3 1      
 Edema 6 2      
Total 85       
  1. Abbreviations: DLI duodenal levodopa infusion, Ext./int. = external or internal, LFV last follow-up visit, mH&Y modified Hoehn and Yahr stage, PEG-J percutaneous endoscopic gastrostomy with jejunal extension tube, UPDRS Unified Parkinson’s Disease Rating Scale. Data are mean values and percentage of total (n) or (range) ± standard deviation (SD).
  2. aMore than one complication can be reported for each visit.